bioRxiv · 10.1101/2022.12.04.519057
Mechanisms of HIV-1 Integrase Resistance to Dolutegravir and Potent Inhibition of Drug Resistant Variants
Abstract
HIV-1 infection depends on the integration of viral DNA into host chromatin. Integration is mediated by the viral enzyme integrase and is blocked by integrase strand transfer inhibitors (INSTIs), first-line antiretroviral therapeutics widely used in the clinic. Resistance to even the best INSTIs is a problem and the mechanisms of resistance are poorly understood. Here, we analyze combinations of the mutations E138K, G140A/S, and Q148H/K/R, which confer resistance to INSTIs. The investigational drug 4d more effectively inhibited the mutants compared with the approved drug Dolutegravir (DTG). We present 11 new cryo-EM structures of drug resistant HIV-1 intasomes bound to DTG or 4d, with better than 3 [A] resolution. These structures, complemented with free energy simulations, virology, and enzymology, explain the mechanisms of DTG resistance involving E138K+G140A/S+Q148H/K/R and show why 4d maintains potency better than DTG. These data establish a foundation for further development of INSTIs that potently inhibit resistant forms in integrase.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Li, M., Passos, D., Shan, Z., Smith, S. J., Sun, Q., Biswas, A., Choudhuri, I., Strutzenberg, T., Haldane, A., Deng, N., Li, Z., Zhao, X.-Z., Burke, T. R., Levy, R. M., Hughes, S. H., Craigie, R., Lyumkis, D.. 2022-12-05. Mechanisms of HIV-1 Integrase Resistance to Dolutegravir and Potent Inhibition of Drug Resistant Variants. https://doi.org/10.1101/2022.12.04.519057
Cite the original work for its findings. Save a collection to share your selection of sources.